Open Access Peer-reviewed Commentary

The argument against crowdfunding Alzheimer's disease research

Main Article Content

MARIO D. GARRETT corresponding author


With pharmaceutical companies’ repeated failures at finding effective interventions for Alzheimer’s disease, together with an increasing reliance on the growing Federal funding for research, there is an emergent opportunity for financing alternate research through crowdfunding. Crowdfunding - where funding is obtained from small donations from a large group of people-has become a new source of funding for medical research. By understanding how the research community has evolved to study Alzheimer’s disease the pitfalls of this strategy can be highlighted. Alzheimer’s disease research is complex. From its inception in the early 1900s, Alzheimer’s disease has been at the center of movement within psychiatry to define the disease on the basis of its biology. Recent emphasis—through the DSM (Diagnostic and Statistical Manual of Mental Disorders), RDoC (Research Diagnostic Criteria), RDoC (Research Domain Criteria) as well as the more recent Framework from the U.S. National Institute on Aging - have supported an exclusive emphasis on biology. But by excluding other aspects of the disease, such as its clinical expression, this research approach will be shown to be faulty and contradictory. So far this approach has resulted in 100% failures. By examining the historical and financial circumstances of the industry centered on Alzheimer’s disease a strong warning is given to the public to mistrust crowdfunding Alzheimer’s disease research. A broader and more inclusive approach is likely to generate a better understanding of the disease and therefore hold better promise for understanding the disease in the long term. Such a nuance approach competes badly with the more binary search for a cure and is less receptive to public support through crowdfunding.

crowdfunding, Alzheimer’s disease, DSM, RDoC

Article Details

How to Cite
GARRETT, M. D. (2019). The argument against crowdfunding Alzheimer’s disease research. Advances in Health and Behavior, 2(1), 49-61.


  1. Popper K. Conjectures and refutations: The growth of scientific knowledge. routledge, 2014.
  2. Kuhn TS. The structure of scientific revolutions. University of Chicago press, 2012.
  3. Sauermann H, Franzoni C, Shafi K. Crowdfunding Scientific Research. National Bureau of Economic Research, 2018.
  4. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 2018, 14(4): 535-562.
  5. Fu C, Chute DJ, Farag ES, et al. Comorbidity in dementia: an autopsy study. Archives of pathology & laboratory medicine, 2004, 128(1): 32-38.
  6. Strobel G. Alzheimer Research Forum Report: Tübingen: The Man Behind the Eponym. Journal of Alzheimer’s Disease, 2007, 11(1): 131-133.
  7. Weuve J, Proust-Lima C, Power MC, et al. Guidelines for reporting methodological challenges and evaluating potential bias in dementia research. Alzheimer’s & dementia, 2015, 11(9): 1098-1109.
  8. Jessen F, Amariglio RE, Van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s & Dementia, 2014, 10(6): 844-852.
  9. Weinberger DR, Glick ID and Klein DF. Whither research domain criteria (RDoC)?: the good, the bad, and the ugly. JAMA psychiatry, 2015, 72(12): 1161-1162.
  10. Au R, Piers RJ and Lancashire L. Back to the future: Alzheimer’s disease heterogeneity revisited. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2015, 1(3): 368.
  11. Snyder J, Turner L and Crooks VA. Crowdfunding for Unproven Stem Cell-Based Interventions. Jama, 2018, 319(18): 1935-1936.
  12. Garrett MD and Valle R. A New Public Health Paradigm for Alzheimer’s Disease Research. SOJ Neurol, 2015, 2(1): 1-9.
  13. Jack Jr CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 2011, 7(3): 257-262.
  14. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 2018, 14(4): 535-562.
  15. Lenzer J. French guidelines are withdrawn after court finds potential bias among authors.
  16. Lehmann HE and Ban TA. The history of the psychopharmacology of schizophrenia. The Canadian Journal of Psychiatry, 1997, 42(2): 152-162.
  17. Kleinman A. Rethinking Psychiatry: From Cultural Category to Personal Experience. New York: Free Press, 1988.
  18. Blashfield RK, Keeley JW, Flanagan EH, et al. The cycle of classification: DSM-I through DSM-5. Annual review of clinical psychology, 2014, 10: 25-51.
  19. Decker HS. The making of DSM-III: A diagnostic manual’s conquest of American psychiatry. Oxford University Press, 2013: 13.
  20. Yasgur BS. Push Is On to Reclassify Schizophrenia as a Neurologic Disease - Medscape, 2018.
  21. Kendell RE, Cooper JE, Gourlay AJ, et al. Diagnostic criteria of American and British psychiatrists. Archives of General Psychiatry, 1971, 25(2): 123-130.
  22. Rosenhan DL. On being sane in insane places. Science, 1973, 179(4070): 250-258.
  23. Spitzer RL, Endicott J and Robins E. Clinical criteria for psychiatric diagnosis and DSM-III. The American journal of psychiatry, 1975.
  24. Feighner JP, Robins E, Guze SB, et al. Diagnostic criteria for use in psychiatric research. Archives of general psychiatry, 1972, 26(1): 57-63.
  25. Livesley WJ. Trait and behavioral prototypes of personality disorder. The American journal of psychiatry, 1986.
  26. Reed GM, Roberts MC, Keeley J, et al. Mental health professionals’ natural taxonomies of mental disorders: implications for the clinical utility of the ICD 11 and the DSM 5. Journal of clinical psychology, 2013, 69(12): 1191-1212.
  27. Roberts MC, Reed GM, Medina-Mora ME, et al. A global clinicians’ map of mental disorders to improve ICD-11: Analysing meta-structure to enhance clinical utility. International Review of Psychiatry, 2012, 24(6): 578-590.
  28. Insel T. Director’s Blog: Transforming Diagnosis, 2013.
  29. Nemeroff CB, Weinberger D, Rutter M, et al. DSM-5: a collection of psychiatrist views on the changes, controversies, and future directions. BMC medicine, 2013, 11(1): 202.
  30. Peterson BS. Research Domain Criteria (RDoC): a new psychiatric nosology whose time has not yet come. Journal of Child Psychology and Psychiatry, 2015, 56(7): 719-722.
  31. Sugino H, Watanabe A, Amada N, et al. Global trends in Alzheimer disease clinical development: increasing the probability of success. Clinical therapeutics, 2015, 37(8): 1632-1642.
  32. Spatt J. Arnold Pick’s concept of dementia. Cortex, 2003, 39(3): 525-531.
  33. Garrett MD. Politics of Anguish: How Alzheimer’s Disease Became the Malady of the 21st Century. Createspace, 2015.
  34. Deane R, Bell RD, Sagare A, et al. Clearance of amyloid-peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 2009, 8(1): 16-30.
  35. Serrano-Pozo A, Mielke ML, Gómez-Isla T, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. The American journal of pathology, 2011, 179(3): 1373-1384.
  36. Schelke MW, Attia P, Palenchar D, et al. Mechanisms of risk reduction in the clinical practice of Alzheimer’s disease prevention. Frontiers in aging neuroscience, 2018, 10: 96.
  37. Garrett MD, Valle R. A century of confusion in researching Alzheimer’s disease. Int J Healthcare, 2016, 2: 13.
  38. Garrett MD and Valle R. A methodological critique of the National Institute of Aging and Alzheimer’s Association Guidelines for Alzheimer’s disease, dementia, and mild cognitive impairments. Dementia, 2016, 15(2): 239-2354.
  39. Bell RD and Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta neuropathologica, 2009, 118(1): 103-113.
  40. Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer’s amyloid-1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. The Journal of clinical investigation, 2000, 106(12): 1489-1499.
  41. Zenaro E, Piacentino G and Constantin G. The blood-brain barrier in Alzheimer’s disease. Neurobiology of disease, 2017: 107.
  42. Garrett MD. A Critique of the 2018 National Institute on Aging’s. Research Framework: Toward a biological definition of Alzheimer’s disease.
  43. Sadler JZ. Values and psychiatric diagnosis. Oxford University Press, 2005.
  44. Langston JW and Palfreman J. The case of the frozen addicts: How the solution of a medical mystery revolutionized the understanding of Parkinson’s disease. IOS Press, 2013.
  45. Langston JW. The MPTP story. Journal of Parkinson’s disease, 2017, 7(s1): S11-19.
  46. Whitehouse PJ. The end of Alzheimer’s disease-From biochemical pharmacology to ecopsychosociology: A personal perspective. Biochemical pharmacology, 2014, 88(4): 677-681.
  47. The LN. Finding a cure for Alzheimer’s disease starts with prevention. The Lancet. Neurology, 2016, 15(7): 649.
  48. Ballenger JF. Framing confusion: Dementia, society, and history. AMA journal of ethics, 2017, 19(7): 713-719.
  49. Braak H, Thal DR, Ghebremedhin E, et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. Journal of Neuropathology & Experimental Neurology, 2011, 70(11): 960-969.
  50. PHRMA. Researching Alzheimer’s Disease: Setbacks and Stepping Stones, 2019.
  51. Cummings JL, Morstorf T and Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimer’s research & therapy, 2014, 6(4): 37.
  52. Cummings J, Reiber C and Kumar P. The price of progress: Funding and financing Alzheimer’s disease drug development. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2018, 4: 330-343.
  53. Vradenburg G. A pivotal moment in Alzheimer’s disease and dementia: how global unity of purpose and action can beat the disease by 2025. Expert review of neurotherapeutics, 2015, 15(1): 73-82.
  54. Scott TJ, O’connor AC, Link AN, et al. Economic analysis of opportunities to accelerate Alzheimer’s disease research and development. Annals of the New York Academy of Sciences, 2014, 1313(1): 17-34.
  55. USNIA. Richard Hodes: NIA We have a budget for FY 2019! NIH Research Blog, 2019.
  56. Carter AJ, Donner A, Lee WH, et al. Establishing a reliable framework for harnessing the creative power of the scientific crowd. PLoS biology, 2017, 15(2): e2001387.
  57. Hayflick L. Comment In: Richard Hodes: NIA We have a budget for FY 2019. NIH, 2019.
  58. Katzman R. The prevalence and malignancy of Alzheimer disease: a major killer. Archives of neurology, 1976, 33(4): 217-218.
  59. Snyder HM, Asthana S, Bain L, et al. Sex biology contributions to vulnerability to Alzheimer’s disease: A think tank convened by the Women’s Alzheimer’s Research Initiative. Alzheimer’s & Dementia, 2016, 12(11): 1186-1196.
  60. Doraiswamy PM, Leon J, Cummings JL, et al. Prevalence and impact of medical comorbidity in Alzheimer’s disease. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2002, 57(3): 173-177.
  61. Sanderson M, Wang J, Davis DR, et al. Co-morbidity associated with dementia. American Journal of Alzheimer’s Disease & Other Dementias, 2002, 17(2): 73-78.
  62. Wagner GS, McClintock SM, Rosenquist PB, et al. Major depressive disorder with psychotic features may lead to misdiagnosis of dementia: a case report and review of the literature. Journal of psychiatric practice, 2011, 17(6): 432.
  63. Guziak CC and Smith JE. Anxiety Misdiagnosed as Dementia? A Complex Case Successfully Treated Using a Multimodal Biofeedback Approach. Biofeedback, 2014, 42(1): 12-15.
  64. Qiu C, De Ronchi D and Fratiglioni L. The epidemiology of the dementias: an update. Current opinion in psychiatry, 2007, 20(4): 380-385.
  65. Nielsen TR, Andersen BB, Kastrup M, et al. Quality of dementia diagnostic evaluation for ethnic minority patients: a nationwide study. Dementia and geriatric cognitive disorders, 2011, 31(5): 388-396.
  66. Black S and Simpson GM. A Call to Action: Dementia Screening of Alzheimer’s Disease in Older African Americans. InThe collective spirit of aging across cultures, 2014: 229-238.
  67. Sayegh P and Knight BG. Assessment and diagnosis of dementia in Hispanic and non-Hispanic White outpatients. The Gerontologist, 2013, 53(5): 760-769.
  68. Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia. New England Journal of Medicine, 2009, 360(22): 2302-2309.
  69. Hardy JA and Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science, 1992, 256(5054): 184-186.
  70. Hock C, Konietzko U, Streffer JR, et al. Antibodies against-amyloid slow cognitive decline in Alzheimer’s disease. Neuron, 2003, 38(4): 547-554.
  71. Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD. Neurology, 2005, 64(1): 94-101.
  72. Gilman S, Koller M, Black RS, et al. Clinical effects of A immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 2005, 64(9): 1553-1562.
  73. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of A 42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. The Lancet, 2008, 372(9634): 216-223.
  74. Iqbal K, Liu F and Gong CX. Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles. Biochemical pharmacology, 2014, 88(4): 631-639.
  75. Goedert M. Oskar Fischer and the study of dementia. Brain, 2008, 132(4): 1102-1111.
  76. Cappa SF. The quest for an Alzheimer therapy. Frontiers in neurology, 2018, 9: 108.
  77. Boche D, Donald J, Love S, et al. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after A 42 immunisation in Alzheimer’s disease. Acta neuropathologica, 2010, 120(1): 13-20.
  78. Li X, Kaida-Yip F and Zabel M. NSAID Use and the Prevention of Alzheimer’s Disease: A Meta-Analysis. Neurology, 2018, 90(15): 184.
  79. Manuel DG, Schultz SE and Kopec JA. Measuring the health burden of chronic disease and injury using health adjusted life expectancy and the Health Utilities Index. Journal of Epidemiology & Community Health, 2002, 56(11): 843-850.
  80. Tanuseputro P, Manuel DG, Leung M, et al. Risk factors for cardiovascular disease in Canada. Canadian Journal of Cardiology, 2003, 19(11): 1249-1260.
  81. Manton KG, Patrick CH and Stallard E. Mortality model based on delays in progression of chronic diseases: alternative to cause elimination model. Public Health Reports, 1980, 95(6): 580.
  82. Interactive H. MetLife Foundation Alzheimer’s survey: what America thinks. A MetLife Foundation commissioned report, 2006.
  83. MIPO-Marist Institute for Public Opinion. Alzheimer’s most feared disease survey for Home Instead Senior Care, 2012.
  84. O’rourke N. Alzheimer’s disease as a metaphor for contemporary fears of aging. Journal of the American Geriatrics Society, 1996, 44(2): 220-221.
  85. Selwood A, Thorgrimsen L and Orrell M. Quality of life in dementia-a one year follow up study. International journal of geriatric psychiatry, 2005, 20(3): 232-237.
  86. Hoe J, Hancock G, Livingston G, et al. Changes in the quality of life of people with dementia living in care homes. Alzheimer Disease and associated disorders, 2009, 23(3): 285.
  87. Bosboom PR, Alfonso H and Almeida OP. Determining the predictors of change in quality of life self-ratings and carer-ratings for community-dwelling people with Alzheimer disease. Alzheimer Disease & Associated Disorders, 2013, 27(4): 363-371.
  88. Beerens HC, Sutcliffe C, Renom-Guiteras A, et al. Quality of life and quality of care for people with dementia receiving long term institutional care or professional home care: the European RightTimePlaceCare study. Journal of the American Medical Directors Association, 2014, 15(1): 54-61.
  89. Beerens HC, Zwakhalen SM, Verbeek H, et al. Change in quality of life of people with dementia recently admitted to long term care facilities. Journal of Advanced Nursing, 2015, 71(6): 1435-1447.
  90. Payne JL, Sheppard JM, Steinberg M, et al. Incidence, prevalence, and outcomes of depression in residents of a long term care facility with dementia. International journal of geriatric psychiatry, 2002, 17(3): 247-253.
  91. Kitwood T. Toward a theory of dementia care: ethics and interaction.
  92. Clare L, Woods RT, Nelis SM, et al. Trajectories of quality of life in early stage dementia: individual variations and predictors of change. International Journal of Geriatric Psychiatry, 2014, 29(6): 616-623.
  93. Bosboom PR, Alfonso H and Almeida OP. Determining the predictors of change in quality of life self-ratings and carer-ratings for community-dwelling people with Alzheimer disease. Alzheimer Disease & Associated Disorders, 2013, 27(4): 363-371.
  94. Pot AM, Deeg DJ and Van Dyck R. Psychological well-being of informal caregivers of elderly people with dementia: changes over time. Aging & Mental Health, 1997, 1(3): 261-268.
  95. Ask H, Langballe EM, Holmen J, et al. Mental health and wellbeing in spouses of persons with dementia: the Nord-Trøndelag health study. BMC Public Health, 2014, 14(1): 413.
  96. Newman M. Is cancer fundraising fuelling quackery?. BMJ, 2018, 362: 3829.
  97. Vox F, Folkers KM, Turi A, et al. Medical Crowdfunding for Scientifically Unsupported or Potentially Dangerous Treatments. JAMA, 2018, 320(16): 1705-1706.